Future prospects and therapeutic potential of streptogramins

Drugs

Volumn 51, Issue SUPPL. 1, 1996, Pages 38-42

  Rubinstein, Ethan ^a   Keller, Nathan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; LINCOSAMIDE DERIVATIVE; MACROLIDE; METICILLIN; PENICILLIN G; STREPTOGRAMIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; ENTEROCOCCUS FAECALIS; FOREIGN BODY; GRAM POSITIVE BACTERIUM; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; OSTEOMYELITIS; SEPSIS; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTEREMIA; FORECASTING; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INCIDENCE; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; VIRGINIAMYCIN;

EID: 0029975183     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199600511-00008     Document Type: Article

References (30)

1. Finland M. Changing etiology of bacterial infections as related to antibacterial therapy. J Infect Dis 1970; 122: 419-31
2. Voss A, Doebbeling BN. The world wide prevalence of methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 1995; 5: 101-6
3. Small PM, Chambers HF. Vancomycin for Staphylococcus aurus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990; 34: 1227-31
4. Geraci JE, Hermans PE. Vancomycin. Mayo Clin Proc 1983; 58: 88-91
5. Galankis N, Giamarellou H, Vlachogiannis N, et al. Poor efficacy of teicoplanin in the treatment of deep-seated staphylococcal infections. Eur J Clin Microbiol Infect Dis 1988; 7 (2): 130-4
6. Finch R. Antibacterial activity of quinupristin/dalfopristin (RP 59500): rationale for clinical use. Drugs 1996; 51 Suppl. 2: 31-7
7. Lorian V, Fernandes F. Synergistic activity of injectable streptogramin RP59500-vancomycin combination [abstract no. E126]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20; San Francisco, California: 107
8. Kang SL, Rybak MJ. In vitro bactericidal activity of RP 59500 (quinupristin/dalfopristin; RP) alone and in various combinations against resistant strains of Enterococcus species and Staphylococcus aureus (SA) [abstract no. E121]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20; San Francisco, California: 107
9. Desnottes JF, Diallo N. Cellular uptake and intracellular bactericidal activity of RP 59500 in murine macrophages. J Antimicrob Chemother 1992; 30 Suppl. A: 7-116
10. Barrière JC, Bouanchaud DH, Desnottes JF, Paris JM. Streptogramin analogues. Expert Opin Invest Drugs 1994; 3 (2): 115-31
11. Etienne SD, Montay G, Le Liboux A, et al. A phase I, doubleblind, placebo-controlled study of the tolerance and pharmacokinetic behaviour of RP 59500. J Antimicrob Chemother 1992; 30 Suppl. A: 123-31
12. Philpot-Howard J, Casewell M. Hospital infection control. London: Saunders Co., 1994
13. Archer GL, Climo MW. Antimicrobial susceptibility of coagulase-negative staphylococci. Antimicrob Agents Chemother 1994; 38: 2231-7
14. Bochud P-Y, Eggiman Ph, Calabdra Th, et al. Bacteremia due to viridans streptococci in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 1994; 18: 25-31
15. Floret D, Stamm D, Chocut P, et al. Streptococcal toxic shock syndrome in children. Intensive Care Med 1992; 18: 175-6
16. Gray GC, Eschamilla J, Hyams KC, et al. Hyperendemic Streptococcus pyogenes prophylaxis with penicillin G benzathine. N Engl J Med 1991; 325: 92-7
17. Eliopoulos G. The ten most common questions about resistant enterococcal infections. Inf Dis Clin Prac 1995; 3: 125-9
18. Anonymous. Vosocomial enterococci resistant to vancomycin. United States 1989-1993. MMWR 1993; 42: 597-600
19. Collins LA, Melanoski GJ, Eliopoulos GM, et al. In vitro activity of RP 59500, an injectable streptogramin antibiotic, acainst vancomycin-resistant. Gram-positive organisms. Antimicrob Agents Chemother 1993; 37 (3): 598-601
20. Casewell MW, Seyed-Akhavani M, Wade J. In vitro activity of RP 59500 against vancomycin-resistant Enterococcus faecium also resistant to > 512 mg/L of gentamicin [abstract no. 1058]. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1993 Oct 17-20; New Orleans, Louisiana: 313
21. Scriver SR, Tyrrell G, Willey BM. In vitro assessment of RP 59500 (RP) against vancomycin-resistant enterococci [abstract no. 1057]. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1993 Oct 17-20; New Orleans, Louisiana: 312
22. Tucker L, Peterson L, Noskin E. Activity of 32 antimicrobial agents alone and in combination against high level vancomycin resistant to Enterococcus faecium [abstract no. 1061]. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1993 Oct 17-20; New Orleans, Louisiana: 313
23. Tenover F. Data on file, Centers for Disease Control and Prevention, Atlanta, Georgia
24. Mahayni R, Perri MB, Dembry LM, et al. Comparative in vitro and bactericidal activity of RP 59500 (quinupristin/ dalfopristin) against multidrug resistant Enterococcus faecium [abstract no. E3]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct 4-7; Orlando, Florida: 27
25. Silber JL, Patel M, Paul SM, et al. Statewide surveillance of isolates of vancomycin-resistant Gram-positive cocci: genotyping of vancomycin resistance and activity of quinupristin/dalfopristin (RP 59500) and other antimicrobials [abstract no. E8]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct 4-7; Orlando, Florida: 48
26. Cerwinka S, Hoffman K, Fayocavitz S, et al. Compassionate use treatment of endocarditis with RP 59500 (quinupristin/ dalfopristin). 3rd International Symposium on Modern Concepts in Endocarditis; 1995 13 Jul; Boston USA: 83
27. Linden P, Pasculle AW, Riddler S, et al. Quinupristin/ dalfopristin (RP 59500) for the treatment of serious infection due to high level vancomycin resistant Enterococcus faecium [abstract no. M68]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct 4-7; Orlando, Florida: 261
28. Lynn WA, Clutterbuck E, Want S, et al. Treatment of CAPD-peritonitis due to glycopeptide-resistant Enterococcus faceium with quinupristin/dalfopristin. Lancet 1994; 344: 1025-6
29. Hofmann J, Cetron MS, Forley MM, et al. The prevalence of drug resistant Streptococcus pneumoniae in Atlanta. N Eng J Med 1995; 333: 481-6
30. Henderson FW, Gilligan PH, Wait K, et al. Nasopharyngeal carriage of antibiotic-resistant pneumococci group day care. J Infect Dis 1988; 157 (2): 256-63